Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Up 8.3 %

Shares of CARA stock opened at $0.29 on Monday. The firm’s 50 day moving average is $0.29 and its 200 day moving average is $0.43. The stock has a market capitalization of $15.80 million, a P/E ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a 12 month low of $0.24 and a 12 month high of $1.40.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The company had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. On average, equities analysts predict that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Cara Therapeutics

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN boosted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after buying an additional 120,660 shares during the period. Disciplined Growth Investors Inc. MN owned approximately 3.54% of Cara Therapeutics worth $499,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.